Reduction of polypharma through innovative drug preparation

Can you present Pikralida?

We are a company operating as part of a hybrid business model. On the one hand, we focus on developing innovative therapies for unsatisfied medical needs, and on the other hand we offer services of a professional contract of contract research (CRO) for biotechnology and pharmaceutical companies. Our developmental efforts focus on a highly strong metaloproteinase inhibitor (MMP) and snake venom metaloproteinase (SVMP), which we develop in therapies in conditions such as neurotrotection after a hug and delighting the snake.

We focus on two main therapeutic roads. First of all, we are developing a new neuroprotective therapy in patients after injury, a space in which there is still no effective long -term treatment methods. Secondly, we aim at the orphan disease: breaking a snake. This is a neglected state in an urgent need for attention and we think that our molecule has strong potential here because of its mechanism of action.

How do you use Thermo Fisher’s Twin Spruder in research?

. Twin screw extruder It plays a key role in our work, especially when the hot alloy is extruded. This technology significantly increases the solubility of our active pharmaceutical components (API), which is crucial for improving drug absorption and effectiveness. It also allows us to develop combination therapies with a fixed dose by embedding various API interfaces in thermoplastic polymer to ensure compatibility and enable controlled release.

How does it help reduce polypharma reduction?

Hot Hot Met Exprusing allows us to formulate complex drug combinations into one dosage form. This is especially important for older patients or people with chronic states who often take many drugs.

By combining therapies into one product and modifying the release profiles accordingly, we can reduce the number of different tablets needed by the patient, effectively dealing with polypharma. It is an innovation focused on a patient that increases adhesion and minimizes potential drug -related interactions.

Why is an extruder on a laboratory scale particularly suitable for your research and development?

We often work with rare or expensive API interfaces, which is why we have to maintain the small size of the party. The laboratory extruder is ideal for minimizing API consumption while effective process development. It is also compact, which is practical for research and development laboratories, which usually have a limited space. Most importantly, it reflects the pilot and production extruder design, which means that the transition to a larger scale production is simple and low.

How important is scalability when moving from the laboratory for commercial production?

This is crucial. The beauty of the Thermo Fisher double extruders is that their laboratory models are designed to resemble equipment on a production scale. This consistency allows for trouble -free technology transfer. We can develop a small -scale process and be sure that it will work similarly on a production scale, which reduces development time and risk.

Are there other processing methods that you examine with a double screw extruder?

Yes, the versatility of the double screw extruder extends beyond the extrudation of the hot alloy. We are also looking for methods such as continuous wet granulation, pelletization and even the production of 3D printing fibers. These options ensure flexibility in creating dosage forms, enabling us to adapt the supply of drugs to specific therapeutic needs and patient groups.

How do you see your technologies affecting the future of drug development?

I believe that the combination of intelligent technologies of drug preparations with precise production tools, such as extruding twin screws, will change the method of developing and supplying drugs. For example, the ability to reduce polyfarmation not only simplifies therapy in patients, but also improves safety and results.

When we study more personalized and complex treatment methods, especially in orphans and CNS disorders, these technologies will be necessary.

What next for Pikralida?

We are moving forward with our main candidates in both neuroprotective areas and a snake. At the same time, we still support biotechnology partners through our CRO services. We are also expanding our development opportunities that will enable us to develop even more innovative forms of dosage in the future.